PeptideKey News

CT-388: The GLP-1 Drug That Never Plateaus [Phase 2 Data]

Roche's CT-388 achieved 22.5% weight loss with no plateau at 48 weeks via biased GLP-1/GIP agonism. Phase 2 data and competitive analysis.

Loading full content...